# Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban

Study · id `cardio:ct-nct07135089` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07135089](<https://clinicaltrials.gov/study/NCT07135089>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07135089

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 870 participants.

## Technical summary

Registry record NCT07135089. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-13 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 870 participants (planned count; ClinicalTrials.gov record NCT07135089, source copy `cardio:ctgov-nct07135089-2025-12-09`, retrieved 2026-10-26)
- Started: 2025-11-13 (actual) (ClinicalTrials.gov record NCT07135089, source copy `cardio:ctgov-nct07135089-2025-12-09`, retrieved 2026-10-26)
- Primary completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07135089, source copy `cardio:ctgov-nct07135089-2025-12-09`, retrieved 2026-10-26)
- Completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT07135089, source copy `cardio:ctgov-nct07135089-2025-12-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07135089, source copy `cardio:ctgov-nct07135089-2025-12-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07135089-2025-12-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban
- Acronym: INSIST-IT2
- Condition: Stroke, Ischemic
- Intervention (Drug): Intravenous tirofiban before endovascular thrombectomy
- Intervention (Drug): Intravenous placebo before endovascular thrombectomy
- Lead sponsor: General Hospital of Shenyang Military Region
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: General Hospital of Shenyang Military Region (`cardio:org-general-hospital-of-shenyang-military-region`)

## Provenance

Content hash: 2e688df041b312e883ebef74de045e740208aa5a7f03e0b7efb0874bc047d328
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
